The GammaTile team is pleased to announce the interim results of the Phase 3 Randomized Controlled Trial, which were recently presented at the 2025 Congress of Neurological Surgeons Annual Meeting. The study found that GammaTile reduced the risk of tumor recurrence or death by more than 50% compared to standard of care (surgery followed by delayed stereotactic radiation). Importantly, these gains were achieved without any increase in treatment-related side effects, reinforcing the safety and efficacy of immediate, targeted radiation delivered at surgery.(1) The findings represent a significant step forward in brain metastasis care and highlight the growing impact of GammaTile in improving patient outcomes. Together, we’re changing what’s possible for patients with brain tumors, delivering immediate radiation when and where it is needed most. Read the press release to learn more: tinyurl.com/8mpnavwj This interim analysis is based on data from 168 of the 230 patients enrolled in the study. Randomization was conducted on a 1:1 basis. All results presented are preliminary and subject to change as additional data become available from the remaining enrolled participants. REFERENCE: Weinberg J, Beckham TH, Lin H, et al. Interim analysis of a phase 3 randomized controlled trial for treatment of newly diagnosed metastatic brain tumors(ROADS, NCT04365374).

We are proud to share that @ECUHealthNC recently treated their 100th patient with GammaTile.   As a Center of Excellence, ECU Health remains steadfast in their commitment to improving outcomes for their patients and this milestone is evidence of that dedication. Their expertise in the GammaTile procedure and demonstrated leadership in patient education will continue to advance care and provide patients with more options. Learn more about ECU Health: na2.hubs.ly/H065_k90   See full prescribing information at na2.hubs.ly/H06606k0

The Phase 3 Results from the Randomized Multicenter ROADS Trial, presented as a late-breaking abstract at the 2026 ASCO Annual Meeting, was recently featured in The Wall Street Journal (@WSJ) article titled "Radiation Device Placed in Brain Cuts Tumor Recurrence, Boosts Survival." Read the article: na2.hubs.ly/H065_f20 See full prescribing information at na2.hubs.ly/H065_5Y0

Join the GammaTile team next week for “Breakthrough in Brachytherapy: Brachytherapy’s Impact on the ROADS Trial in Newly Diagnosed Brain Metastases” at the American Brachytherapy Society 2026 Annual Meeting. Reserve your spot: na2.hubs.ly/H0657yn0 See full prescribing information at na2.hubs.ly/H0655_x0

We’re pleased to announce the successful raise of $100 million in our Series E equity financing round. The financing was led by new investor Viking Global Investors with participation from key existing investors, including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures.   This milestone underscores the ongoing confidence in GT Medical Technologies’ mission to improve outcomes for patients with operable brain tumors.   Read the press release: na2.hubs.ly/H062vJr0   See full prescribing information at na2.hubs.ly/H062vHx0

Today is World Brain Tumor Day. At GammaTile, we’re honored to be part of a community working tirelessly to advance treatment for patients with operable brain tumors. Today and every day, we stand with patients, caregivers, clinicians, and advocates. This day is a powerful reminder of our commitment to making a meaningful difference in brain tumor care. #WorldBrainTumorDay #DefeatBrainTumors #GammaTile See full prescribing information at na2.hubs.ly/H061CH90

#ABSBrachy26 kicks off this month! Join the GammaTile team for an evening of conversation and connection as we reflect on the recent Full Analysis of the Phase 3 ROADS Trial data presented as a Late-Breaking Abstract on May 30, 2026 at the ASCO Annual Meeting, celebrating progress, partnership, and what's next in the future of brain tumor care. Reserve your spot: na2.hubs.ly/H05YMHN0 See full prescribing information at na2.hubs.ly/H05YRlT0

Learn more about GammaTile at #ABSBrachy26! Stop by our booth and join our Friday evening reception to hear about our Phase 3 Full 230 Patient Analysis of the ROADS Trial for Newly Diagnosed Brain Metastases. Reserve your spot: na2.hubs.ly/H05ThW80 See full prescribing information at na2.hubs.ly/H05Tcfx0

A postage stamp-sized implant eliminates a dangerous waiting period that has long worsened outcomes for cancer patients. on.wsj.com/4fcEkOx

NEW DATA New randomized, multicenter ROADS Trial Phase 3 Results — presented today in a late-breaking abstract at the 2026 ASCO Annual Meeting — demonstrate that surgery with GammaTile significantly improves upon the current standard of care in patients with newly diagnosed brain metastases. The study demonstrated that GammaTile cesium-131 collagen tile-based radiation therapy (TBRT), implanted directly into the tumor site during surgery, resulted in dramatically lower rates of tumor regrowth, a superior likelihood of living longer without recurrence, and significantly improved overall survival compared to standard stereotactic radiation therapy (SRT). These findings highlight the value of immediate, targeted radiation therapy and collaborative clinical research in advancing care for patients with newly diagnosed operable brain metastases. Read the abstract: na2.hubs.ly/H05Q-jj0 Reference: Weinberg J. J Clin Oncol 44, 2026 (suppl 17; abstr LBA2000) See full prescribing information at na2.hubs.ly/H05Q_Nb0

Join us today at 3 PM CDT at ASCO 2026 for “Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.” Learn more: na2.hubs.ly/H05QZRQ0 Not attending ASCO? Sign up to see the data once released: na2.hubs.ly/H05Q-fJ0 See full prescribing information at na2.hubs.ly/H05Q-fK0

“Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases” is being presented tomorrow at ASCO 2026! Hear the Phase 3 Results for the ROADS Trial at 3PM CDT. Learn more: na2.hubs.ly/H05QnJS0 Not attending ASCO? Sign up to see the data once released: na2.hubs.ly/H05QnQm0 See full prescribing information at na2.hubs.ly/H05Qp7x0

Brain Tumor Awareness Month may be coming to a close, but awareness is just the beginning. At GammaTile, our commitment to the brain tumor community is built into everything we do. We remain focused on what matters most: supporting patients on their treatment journey and advancing brain tumor care. #BrainTumorAwarenessMonth #BTAM #GammaTile See full safety information at na2.hubs.ly/H05QnQj0

In this prospective, multi-center observational study demonstrates that resection and GammaTile for aggressive, recurrent meningiomas resulted in encouraging local control and low adverse event rate. Specifically, the study found that for all Grades combined, local control at 6, 12, and 15 months were 94.4%, 78.3%, and 67.0%. These findings represent a meaningful step forward and a promising approach in the treatment of recurrent meningioma. Read the abstract: na2.hubs.ly/H05NHQy0 #BrainTumorAwarenessMonth #BTAM #GammaTile #RecurrentMeningioma REFERENCE: Desai B, et al. Neuro-Oncology. 2025;27(Suppl 5):v107. See full prescribing information at na2.hubs.ly/H05NQVG0

Treatment is challenging for recurrent meningioma, especially for previously irradiated tumors. Neurosurgeon Joseph Zabramski, MD, shares his perspective on where GammaTile belongs in the treatment discussion. Dr. Zabramski is a research investigator in the Barrow Aneurysm and AVM Research Center at Barrow Neurological Institute. #BrainTumorAwarenessMonth #BTAM #GammaTile #RecurrentMeningioma Quotes are based on the personal experience and learnings of the featured healthcare professionals. See full prescribing information at na2.hubs.ly/H05MrM00

Mark your calendars for the American Society of Clinical Oncology Annual Meeting! Hear the oral abstract session on GESTALT Clinical Trial Outcomes on Sunday, May 31st, followed by a session on the BRIDGES Clinical Trial on Monday, June 1st. Learn more about the GESTALT session: meetings.asco.org/meetings/2… Learn more about the BRIDGES session: meetings.asco.org/meetings/2… See full prescribing information at na2.hubs.ly/H05MgW-0

Brain Tumor Awareness Month wraps up this week, but not before a final clinical spotlight on recurrent meningioma. This prospective, multi-center observational study demonstrates that resection and GammaTile for aggressive, recurrent meningiomas resulted in encouraging local control and low adverse event rate. Check back in tomorrow to hear from neurosurgeon Joseph Zabramski, MD, about how GammaTile fits into the treatment plan for recurrent meningioma. Read the abstract: na2.hubs.ly/H05LcxF0 #BrainTumorAwarenessMonth #BTAM #GammaTile #RecurrentMeningioma REFERENCE: Desai B, et al. Neuro-Oncology. 2025;27(Suppl 5):v107. See full prescribing information at na2.hubs.ly/H05LcHT0

ASCO 2026 is right around the corner! Join the GammaTile team this Saturday for “Results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.” Learn more: na2.hubs.ly/H05LcBj0 Not attending ASCO? Sign up to see the data once released: na2.hubs.ly/H05Lf-y0 See full prescribing information at na2.hubs.ly/H05LhYQ0

Learn more about BRIDGES, our phase 3 randomized trial of immediate postoperative cesium-131 tile-based radiation therapy followed by abbreviated chemoradiation for newly diagnosed glioblastoma, at the American Society of Clinical Oncology Annual Meeting. View the poster from 1:30-4:30 CDT in Hall A on Monday, June 1st. We hope to see you there! Learn more: na2.hubs.ly/H05J2qD0 See full prescribing information at na2.hubs.ly/H05J1l40